scholarly journals NEURAL STEM CELLS FOR BRAIN AND SPINAL CORD REPAIR * Tanya Zigova, Evan Snyder and Paul Sanberg, editors. * 2002. Totowa (NJ) * Humana Press * Price $149.50. ISBN 1588290034 * STILL LIVES--NARRATIVES OF SPINAL CORD INJURY * Jonathan Cole * 2004. Harvard (MA): Bradford Books, MIT Press * Price  18.95. * ISBN 0262033151 * STEM CELL RESEARCH--NEW FRONTIERS IN SCIENCE AND ETHICS * Nancy E. Snow, editor. * 2003. Notre Dame (IN) * University of Notre Dame Press * Price $25.00. * ISBN 0268017786

Brain ◽  
2004 ◽  
Vol 127 (12) ◽  
pp. 2779-2782
Author(s):  
A. Coles
2005 ◽  
Vol 27 (8) ◽  
pp. 812-819 ◽  
Author(s):  
Hajime Kimura ◽  
Masahide Yoshikawa ◽  
Ryousuke Matsuda ◽  
Hayato Toriumi ◽  
Fumihiko Nishimura ◽  
...  

2019 ◽  
Vol 41 (1-2) ◽  
pp. 79-93 ◽  
Author(s):  
Shen Li ◽  
Jiao Zheng ◽  
Linlin Chai ◽  
Mengsi Lin ◽  
Ruocheng Zeng ◽  
...  

Oligodendrocyte progenitor cells (OPCs) may have beneficial effects in cell replacement therapy of neurodegenerative disease owing to their unique capability to differentiate into myelinogenic oligodendrocytes (OLs) in response to extrinsic signals. Therefore, it is of significance to establish an effective differentiation methodology to generate highly pure OPCs and OLs from some easily accessible stem cell sources. To achieve this goal, in this study, we present a rapid and efficient protocol for oligodendroglial lineage differentiation from mouse neural stem cells (NSCs), rat NSCs, or mouse embryonic stem cell-derived neuroepithelial stem cells. In a defined culture medium containing Smoothened Agonist, basic fibroblast growth factor, and platelet-derived growth factor-AA, OPCs could be generated from the above stem cells over a time course of 4–6 days, achieving a cell purity as high as ∼90%. In particular, these derived OPCs showed high expandability and could further differentiate into myelin basic protein-positive OLs within 3 days or alternatively into glial fibrillary acidic protein-positive astrocytes within 7 days. Furthermore, transplantation of rodent NSC-derived OPCs into injured spinal cord indicated that it is a feasible strategy to treat spinal cord injury. Our results suggest a differentiation strategy for robust production of OPCs and OLs from rodent stem cells, which could provide an abundant OPC source for spinal cord injury.


Neurotrauma ◽  
2018 ◽  
pp. 431-444
Author(s):  
Ping Wu ◽  
Mingliang Yang ◽  
Yan Hao ◽  
Shiqing Feng ◽  
Jianjun Li

Traumatic spinal cord injury (SCI), a devastating disorder that severely affects the quality of life in patients, currently lacks effective therapies. Stem cell research offers a promising option to facilitate spinal cord repair. This chapter provides an overview of the major types of stem cells being used in preclinical animal studies and clinical trials to treat SCI, including mesenchymal, neural, hematopoietic, embryonic, and induced pluripotent stem cells. The authors summarize the beneficial effects of stem cells as a potential new therapeutic approach, but also raise the concerns of the limitation and challenges the field is facing, and suggest future directions.


2020 ◽  
Vol 14 ◽  
Author(s):  
Pieter Vancamp ◽  
Lucile Butruille ◽  
Barbara A. Demeneix ◽  
Sylvie Remaud

2014 ◽  
Vol 9 (24) ◽  
pp. 2197 ◽  
Author(s):  
Lifeng Yang ◽  
Zhi Li ◽  
Wei Zhao ◽  
Wei Liu ◽  
Ye Zhou ◽  
...  

2020 ◽  
Vol 15 (4) ◽  
pp. 321-331 ◽  
Author(s):  
Zhe Gong ◽  
Kaishun Xia ◽  
Ankai Xu ◽  
Chao Yu ◽  
Chenggui Wang ◽  
...  

Spinal Cord Injury (SCI) causes irreversible functional loss of the affected population. The incidence of SCI keeps increasing, resulting in huge burden on the society. The pathogenesis of SCI involves neuron death and exotic reaction, which could impede neuron regeneration. In clinic, the limited regenerative capacity of endogenous cells after SCI is a major problem. Recent studies have demonstrated that a variety of stem cells such as induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), Mesenchymal Stem Cells (MSCs) and Neural Progenitor Cells (NPCs) /Neural Stem Cells (NSCs) have therapeutic potential for SCI. However, the efficacy and safety of these stem cellbased therapy for SCI remain controversial. In this review, we introduce the pathogenesis of SCI, summarize the current status of the application of these stem cells in SCI repair, and discuss possible mechanisms responsible for functional recovery of SCI after stem cell transplantation. Finally, we highlight several areas for further exploitation of stem cells as a promising regenerative therapy of SCI.


2013 ◽  
Vol 2 (10) ◽  
pp. 731-744 ◽  
Author(s):  
Christopher J. Sontag ◽  
Hal X. Nguyen ◽  
Noriko Kamei ◽  
Nobuko Uchida ◽  
Aileen J. Anderson ◽  
...  

2010 ◽  
Vol 19 (10) ◽  
pp. 1325-1337 ◽  
Author(s):  
Gan Wang ◽  
Qiang Ao ◽  
Kai Gong ◽  
Huancong Zuo ◽  
Yandao Gong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document